Moreover, in a phase III trial, cilengitide was assessed in combination with chemoradiotherapy (temozolomide) in patients bearing newly diagnosed glioblastoma with methylated O-6-methylguanine-DNA methyltransferase (MGMT) promoter (a prognostic biomarker for glioblastoma). The gene discussed is MGMT; the disease is glioblastoma.